Market research
SABS SAB Biotherapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 318M
- P/E ratio
- 14.0
- Analyst target
- 11.6364
- Dividend yield
- Not available
- Beta
- 0.54
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US78397T2024
- Market cap
- 318M
- P/E ratio
- 14.0
- Analyst target
- 11.6364
- Dividend yield
- Not available
- Beta
- 0.54
About
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the SABS discussion.
No comments yet
Start a focused discussion about SABS.